ASH 2023: Exploring Therapeutic Advancements for Chronic Lymphocytic Leukemia - Episode 8

Expert Perspectives on Navigating Treatment Selection with BTKis in CLL

, , , , ,

Faculty provide insights into the selection of BTK inhibitors, emphasizing the role of efficacy, toxicity, and quality of life data in treatment decisions, and exploring the impact of MAIC data.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Current Front-Line Treatment Options for CLL in 2023
    EP. 2: Exploring BTKi Monotherapy in CLL: Long-Term Updates from ELEVATE-TN and SEQUOIA
    EP. 3: Strategies for Managing Treatment-Naïve CLL with High-Risk Features
    EP. 4: Impact of Off-Target AEs and Treatment Resistance on Evolving 1L Therapy Strategies for CLL
    EP. 5: Exploring the Role of BTKi-Based Combination Therapies for Front-line Management of CLL
    EP. 6: Treatment Sequencing Strategies for R/R CLL: Impact of Prior 1L Therapy
    EP. 7: Navigating BTKi Therapy in R/R CLL: Updates from ELEVATE-RR and ALPINE
    Now Viewing
    EP. 8: Expert Perspectives on Navigating Treatment Selection with BTKis in CLL
    EP. 9: Expert Insights into Navigating Cardiovascular Risks with BTKi Therapy
    EP. 10: Treatment Resistance with Covalent BTKis: Translating Data into Clinical Practice
    EP. 11: Role of Non-Covalent BTKis in R/R CLL: Updates from Ongoing BRUIN and Bellwave Trials
    EP. 12: Emerging Data Surrounding Mechanisms of Resistance to Non-Covalent BTKis
    EP. 13: Expert Insights into Investigation Therapies for CLL
    EP. 14: Future Perspectives on the Treatment Landscape for CLL
    x